Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psychiatric issues in multiple sclerosis.

Lydia A Chwastiak1, Dawn M Ehde

  • 1Department of Psychiatry, Yale University School of Medicine, Yale New Haven Psychiatric Hospital, 184 Liberty Street, New Haven, CT 06519, USA. lydia.chwastiak@yale.edu

The Psychiatric Clinics of North America
|October 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining state and trait resilience in individuals with spinal cord injury and chronic pain: A daily and longitudinal analysis.

Rehabilitation psychology·2026
Same author

Does Depressed Mood Affect Accuracy of Perceptions of Cognitive Function in Multiple Sclerosis? The Role of Momentary Depressive Symptoms in the Correspondence Between Subjective and Objective Cognition in Multiple Sclerosis.

Archives of physical medicine and rehabilitation·2026
Same author

Comparing Low and High Recovery Expectations Among Those with Lumbar Spinal Stenosis: A Network Analysis.

Pain medicine (Malden, Mass.)·2026
Same author

Examining the Impact of Perceived and Objective Cognitive Function on Social Participation in Individuals With Multiple Sclerosis.

Archives of physical medicine and rehabilitation·2026
Same author

Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.

Archives of physical medicine and rehabilitation·2026
Same author

Potential mediators of the effects of clinical hypnosis, mindfulness meditation, and pain education on chronic pain in Veterans.

The journal of pain·2026
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

Major depressive disorder (MDD) and anxiety are common in multiple sclerosis (MS), impacting treatment adherence and quality of life. More research is needed on effective treatments for depression in MS patients.

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Psychology

Background:

  • Major depressive disorder (MDD) and anxiety disorders are highly prevalent in patients with multiple sclerosis (MS).
  • These mental health conditions are linked to reduced treatment adherence, poorer functional status, and diminished quality of life in MS patients.
  • Despite available treatments for MDD, it remains underdiagnosed and undertreated by MS healthcare providers.

Purpose of the Study:

  • To highlight the prevalence and impact of MDD and anxiety disorders in individuals with MS.
  • To discuss the challenges of treating depression in MS, including pharmacotherapy.
  • To emphasize the need for further research, particularly randomized controlled trials, on depression treatment in MS.

Main Methods:

  • Review of existing literature on mental health disorders in MS.

Related Experiment Videos

  • Discussion of treatment challenges, including pharmacotherapy and symptom overlap.
  • Identification of research gaps concerning anxiety disorders, substance use disorders, and serious mental illnesses in MS populations.

    • Main Results:

    • MDD and anxiety disorders are common comorbidities in MS.
    • Treatment of depression in MS is complicated by symptom overlap and potential side effects of pharmacotherapy.
    • There is a lack of rigorous studies on the prevalence and impact of various mental health conditions in MS.

    Conclusions:

    • Effective treatments for MDD exist but are underutilized in the MS population.
    • Further research, including large-scale randomized controlled trials, is essential to optimize depression pharmacotherapy for MS patients.
    • More investigation is needed into the prevalence and effects of anxiety disorders and other serious mental illnesses in individuals with MS.